0001193125-23-078017.txt : 20230323 0001193125-23-078017.hdr.sgml : 20230323 20230323170704 ACCESSION NUMBER: 0001193125-23-078017 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230317 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230323 DATE AS OF CHANGE: 20230323 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Healthwell Acquisition Corp. I CENTRAL INDEX KEY: 0001845013 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 861911840 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40697 FILM NUMBER: 23757009 BUSINESS ADDRESS: STREET 1: 1001 GREEN BAY RD. #227 CITY: WINNETKA STATE: IL ZIP: 60093 BUSINESS PHONE: 847-612-3359 MAIL ADDRESS: STREET 1: 1001 GREEN BAY RD. #227 CITY: WINNETKA STATE: IL ZIP: 60093 8-K 1 d464704d8k.htm 8-K 8-K
false 0001845013 0001845013 2023-03-17 2023-03-17 0001845013 hwelu:UnitsEachConsistingOfOneShareOfClassACommonStockAndOneHalfOfOneRedeemableWarrantMember 2023-03-17 2023-03-17 0001845013 hwelu:ClassACommonStockParValue0.0001PerShareMember 2023-03-17 2023-03-17 0001845013 hwelu:RedeemableWarrantsEachWarrantExercisableForOneShareOfClassACommonStockFor11.50PerShareMember 2023-03-17 2023-03-17

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 17, 2023

 

 

Healthwell Acquisition Corp. I

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40697   86-1911840
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

1001 Green Bay Rd, #227

Winnetka, IL 60093

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (847) 230-9162

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

  

Name of each exchange
on which registered

Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant   HWELU    The Nasdaq Stock Market LLC
Class A common stock, par value $0.0001 per share   HWEL    The Nasdaq Stock Market LLC
Redeemable warrants, each warrant exercisable for one share of Class A common stock for $11.50 per share   HWELW    The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


Item 1.01. Entry into a Material Definitive Agreement.

On March 17, 2023, Healthwell Acquisition Corp. I (the “Company”) issued an unsecured promissory note (the “Working Capital Note”) in the principal amount of up to $750,000 to Healthwell Acquisition Corp. I Sponsor LLC, a Delaware limited liability company (the “Sponsor”) for working capital purposes. The Working Capital Note bears no interest and is due and payable upon the earlier to occur of (i) the date on which the Company’s initial business combination is consummated and (ii) the liquidation of the Company on or before August 5, 2023, or such later liquidation date as may be approved by the Company’s stockholders. At the election of the Sponsor, the unpaid principal amount of the Working Capital Note may be converted into warrants of the Company (the “Conversion Warrants”) with the total Conversion Warrants so issued equal to: (x) the portion of the principal amount of the Working Capital Note being converted divided by (y) $1.00, rounded up to the nearest whole number of warrants.

The issuance of the Working Capital Note was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended.

The foregoing description is qualified in its entirety by reference to the Working Capital Note, a copy of which is attached as Exhibit 10.1 hereto and is incorporated herein by reference.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The disclosure contained in Item 1.01 of this Current Report on Form 8-K is incorporated by reference in this Item 2.03.

Item 3.02 Unregistered Sales of Equity Securities.

The disclosure contained in Item 1.01 of this Current Report on Form 8-K is incorporated by reference in this Item 3.02.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
Number
  

Title

10.1    Promissory Note, dated March 17, 2023.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: March 23, 2023   Healthwell Acquisition Corp. I
  By:  

/s/ Alyssa Rapp

    Name:   Alyssa Rapp
    Title:   Chief Executive Officer and Director
EX-10.1 2 d464704dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

PROMISSORY NOTE

 

Principal Amount: Up to $750,000    Dated as of March 17, 2023
   New York, New York

Healthwell Acquisition Corp. I, a Delaware corporation (“Maker”), promises to pay to the order of Healthwell Acquisition Corp. I Sponsor LLC, a Delaware limited liability company, or its registered assigns or successors in interest or order (“Payee”), the principal sum of up to Seven Hundred Fifty Thousand Dollars ($750,000) in lawful money of the United States of America, on the terms and conditions described below. All payments on this Note shall be made by check or wire transfer of immediately available funds or as otherwise determined by Maker to such account as Payee may from time to time designate by written notice in accordance with the provisions of this Note.

1.    Repayment. The principal balance of this Note shall be payable on the earliest to occur of: (i) the date on which Maker consummates its initial business combination and (ii) the date that the winding up of Maker is effective (such date, the “Maturity Date”). The principal balance may be prepaid at any time, at the election of Maker. Under no circumstances shall any individual, including but not limited to any officer, director, employee or stockholder of Maker, be obligated personally for any obligations or liabilities of the Maker hereunder.

2.    Interest. This Note shall be non-interest bearing.

3.    Drawdown Requests. Maker and Payee agree that Maker may request up to Seven Hundred Fifty Thousand Dollars ($750,000)] for costs reasonably related to Maker’s initial business combination of its securities. The principal of this Note may be drawn down from time to time prior to the earlier of: (i) the date on which Maker consummates its initial business combination and (ii) the date that the winding up of Maker is effective, upon written request from Maker to Payee (each, a “Drawdown Request”). Each Drawdown Request must state the amount to be drawn down, and must not be an amount less than Two Thousand Five Hundred Dollars ($2,500) unless agreed upon by Maker and Payee. Payee shall fund each Drawdown Request no later than five (5) business days after receipt of a Drawdown Request; provided, however, that the maximum amount of drawdowns collectively under this Note is Seven Hundred Fifty Thousand Dollars ($750,000). Once an amount is drawn down under this Note, it shall not be available for future Drawdown Requests even if prepaid. No fees, payments or other amounts shall be due to Payee in connection with, or as a result of, any Drawdown Request by Maker. Notwithstanding the foregoing, all payments shall be applied first to payment in full of any costs incurred in the collection of any sum due under this Note, including (without limitation) reasonable attorneys’ fees, and then to the reduction of the unpaid principal balance of this Note.

4.    Application of Payments. All payments received by Payee pursuant to this Note shall be applied first to the payment in full of any costs incurred in the collection of any sum due under this Note, including (without limitation) reasonable attorney’s fees, and then to the reduction of the unpaid principal balance of this Note.

5.    Events of Default. The following shall constitute an event of default (“Event of Default”):

(a)    Failure to Make Required Payments. Failure by Maker to pay the principal amount due pursuant to this Note within five (5) business days of the Maturity Date.

(b)    Voluntary Bankruptcy, Etc. The commencement by Maker of a voluntary case under any applicable bankruptcy, insolvency, reorganization, rehabilitation or other similar law, or the consent by it to the appointment of or taking possession by a receiver, liquidator, assignee, trustee, custodian, sequestrator (or other similar official) of Maker or for any substantial part of its property, or the making by it of any assignment for the benefit of creditors, or the failure of Maker generally to pay its debts as such debts become due, or the taking of corporate action by Maker in furtherance of any of the foregoing.

 

1


(c)    Involuntary Bankruptcy, Etc. The entry of a decree or order for relief by a court having jurisdiction in the premises in respect of Maker in an involuntary case under any applicable bankruptcy, insolvency or other similar law, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) of Maker or for any substantial part of its property, or ordering the winding-up or liquidation of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of 60 consecutive days.

6.    Remedies.

(a)    Upon the occurrence of an Event of Default specified in Section 5(a) hereof, Payee may, by written notice to Maker, declare this Note to be due immediately and payable, whereupon the unpaid principal amount of this Note, and all other amounts payable hereunder, shall become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived, anything contained herein or in the documents evidencing the same to the contrary notwithstanding.

(b)    Upon the occurrence of an Event of Default specified in Sections 5(b) and 5(c) hereof, the unpaid principal balance of this Note and all other amounts payable hereunder, shall automatically and immediately become due and payable, in all cases without any action on the part of Payee.

7.    Waivers. Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment for payment, demand, notice of dishonor, protest, and notice of protest with regard to this Note, all errors, defects and imperfections in any proceedings instituted by Payee under the terms of this Note, and all benefits that might accrue to Maker by virtue of any present or future laws exempting any property, real or personal, or any part of the proceeds arising from any sale of any such property, from attachment, levy or sale under execution, or providing for any stay of execution, exemption from civil process, or extension of time for payment; and Maker agrees that any real or personal property that may be levied upon pursuant to a judgment obtained by virtue hereof, on any writ of execution issued hereon, may be sold upon any such writ in whole or in part in any order desired by Payee.

8.    Unconditional Liability. Maker hereby waives all notices in connection with the delivery, acceptance, performance, default, or enforcement of the payment of this Note, and agrees that its liability shall be unconditional, without regard to the liability of any other party, and shall not be affected in any manner by any indulgence, extension of time, renewal, waiver or modification granted or consented to by Payee, and consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by Payee with respect to the payment or other provisions of this Note, and agrees that additional makers, endorsers, guarantors, or sureties may become parties hereto without notice to Maker or affecting Maker’s liability hereunder.

9.    Notices. All notices, statements or other documents which are required or contemplated by this Note shall be: (i) in writing and delivered personally or sent by first class registered or certified mail, overnight courier service or facsimile or electronic transmission to the address designated in writing, (ii) by facsimile to the number most recently provided to such party or such other address or fax number as may be designated in writing by such party and (iii) by electronic mail, to the electronic mail address most recently provided to such party or such other electronic mail address as may be designated in writing by such party. Any notice or other communication so transmitted shall be deemed to have been given on the day of delivery, if delivered personally, on the business day following receipt of written confirmation, if sent by facsimile or electronic transmission, one (1) business day after delivery to an overnight courier service or five (5) days after mailing if sent by mail.

10.    Construction. THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF DELAWARE, WITHOUT REGARD TO THE CONFLICT OF LAWS PROVISIONS THEREOF.

11.    Severability. Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

 

2


12.    Trust Waiver. Notwithstanding anything herein to the contrary, Payee hereby waives any claim in or to any distribution of or from the trust account (the “Trust Account”) established in connection with Maker’s initial public offering (the “IPO”), and hereby agrees not to seek recourse, reimbursement, payment or satisfaction for any claim against the Trust Account for any reason whatsoever; provided, however, that upon the consummation of the initial business combination, Maker shall repay the principal balance of this Note out of the proceeds released to Maker from the Trust Account.

13.    Amendment; Waiver. Any amendment hereto or waiver of any provision hereof may be made with, and only with, the written consent of Maker and Payee.

14.    Assignment. No assignment or transfer of this Note or any rights or obligations hereunder may be made by any party hereto (by operation of law or otherwise) without the prior written consent of the other party hereto and any attempted assignment without the required consent shall be void; provided, however, that the foregoing shall not apply to an affiliate of Payee who agrees to be bound to the terms of this Note.

15.    Conversion.

(a)    Notwithstanding anything contained in this Note to the contrary, at Payee’s option, at any time prior to payment in full of the principal balance of this Note, Payee may elect to convert all or any portion of the unpaid principal balance of this Note into that number of warrants, each exercisable for one share of Class A common stock of the Maker (the “Conversion Warrants”), equal to: (x) the portion of the principal amount of this Note being converted pursuant to this Section 15, divided by (y) $1.00, rounded up to the nearest whole number of warrants. The Conversion Warrants shall be identical to the warrants issued by the Maker to the Payee in a private placement upon consummation of the Maker’s initial public offering. The Conversion Warrants and their underlying securities, and any other equity security of Maker issued or issuable with respect to the foregoing by way of a stock dividend or stock split or in connection with a combination of stocks, recapitalization, amalgamation, consolidation or reorganization, shall be entitled to the registration rights set forth in Section 15 hereof.

(b)    Upon any complete or partial conversion of the principal amount of this Note, (i) such principal amount shall be so converted and such converted portion of this Note shall become fully paid and satisfied, (ii) Payee shall surrender and deliver this Note, duly endorsed, to Maker or such other address which Maker shall designate against delivery of the Conversion Warrants, (iii) Maker shall promptly deliver a new duly executed Note to Payee in the principal amount that remains outstanding, if any, after any such conversion and (iv) in exchange for all or any portion of the surrendered Note, Maker shall, at the direction of Payee, deliver to Payee (or its members or their respective affiliates) (Payee or such other persons, the “Holders”) the Conversion Warrants, which shall bear such legends as are required, in the opinion of counsel to Maker or by any other agreement between Maker and Payee and applicable state and federal securities laws.

(c)    The Holders shall pay any and all issue and other taxes that may be payable with respect to any issue or delivery of the Conversion Warrants upon conversion of this Note pursuant hereto; provided, however, that the Holders shall not be obligated to pay any transfer taxes resulting from any transfer requested by the Holders in connection with any such conversion.

(d)    The Conversion Warrants shall not be issued upon conversion of this Note unless such issuance and such conversion comply with all applicable provisions of law.

16.    Registration Rights.

(a)    Reference is made to that certain Registration Rights Agreement between Maker and the parties thereto, dated as of August 2, 2021 (the “Registration Rights Agreement”). All capitalized terms used in this Section 16 shall have the same meanings ascribed to them in the Registration Rights Agreement.

(b)    At any time and from time to time on or after the date the Maker consummates a Business Combination, the Holders shall be entitled to make a Demand Registration, which shall be subject to the same provisions as set forth in Section 2.1 of the Registration Rights Agreement.

 

3


(c)    The Holders shall also be entitled to include the Conversion Warrants and their underlying securities in the Maker’s Piggyback Registration, which shall be subject to the same provisions as set forth in Section 2.2 of the Registration Rights Agreement; provided, however, that in the event that an underwriter advises Maker that the Maximum Number of Securities has been exceeded with respect to a Piggyback Registration, the Holders’ Conversion Warrants and underlying securities shall not be entitled to priority for inclusion in such Piggyback Registration.

(d)    Except as set forth above, the Holders and Maker, as applicable, shall have all of the same rights, duties and obligations set forth in the Registration Rights Agreement.

[Signature page follows]

 

4


IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed by the undersigned as of the day and year first above written.

 

HEALTHWELL ACQUISITION CORP. I
By:  

/s/ Alyssa Rapp

  Name: Alyssa Rapp
  Title: Chief Executive Officer

 

5

EX-101.SCH 3 hwelu-20230317.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 hwelu-20230317_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 hwelu-20230317_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Units Each Consisting Of One Share Of Class A Common Stock And One Half Of One Redeemable Warrant [Member] Units Each Consisting Of One Share Of Class A Common Stock And One Half Of One Redeemable Warrant [Member] Class A Common Stock Par Value 0.0001 Per Share [Member] Class A Common Stock Par Value 0.0001 Per Share [Member] Redeemable Warrants Each Warrant Exercisable For One Share Of Class A Common Stock For 11.50 Per Share [Member] Redeemable Warrants Each Warrant Exercisable For One Share Of Class A Common Stock For 11.50 Per Share [Member] EX-101.PRE 6 hwelu-20230317_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
Mar. 17, 2023
Document And Entity Information [Line Items]  
Amendment Flag false
Entity Central Index Key 0001845013
Document Type 8-K
Document Period End Date Mar. 17, 2023
Entity Registrant Name Healthwell Acquisition Corp. I
Entity Incorporation State Country Code DE
Entity File Number 001-40697
Entity Tax Identification Number 86-1911840
Entity Address, Address Line One 1001 Green Bay Rd
Entity Address, Address Line Two #227
Entity Address, City or Town Winnetka
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60093
City Area Code (847)
Local Phone Number 230-9162
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Units Each Consisting Of One Share Of Class A Common Stock And One Half Of One Redeemable Warrant [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant
Trading Symbol HWELU
Security Exchange Name NASDAQ
Class A Common Stock Par Value 0.0001 Per Share [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Class A common stock, par value $0.0001 per share
Trading Symbol HWEL
Security Exchange Name NASDAQ
Redeemable Warrants Each Warrant Exercisable For One Share Of Class A Common Stock For 11.50 Per Share [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Redeemable warrants, each warrant exercisable for one share of Class A common stock for $11.50 per share
Trading Symbol HWELW
Security Exchange Name NASDAQ
XML 8 d464704d8k_htm.xml IDEA: XBRL DOCUMENT 0001845013 2023-03-17 2023-03-17 0001845013 hwelu:UnitsEachConsistingOfOneShareOfClassACommonStockAndOneHalfOfOneRedeemableWarrantMember 2023-03-17 2023-03-17 0001845013 hwelu:ClassACommonStockParValue0.0001PerShareMember 2023-03-17 2023-03-17 0001845013 hwelu:RedeemableWarrantsEachWarrantExercisableForOneShareOfClassACommonStockFor11.50PerShareMember 2023-03-17 2023-03-17 false 0001845013 8-K 2023-03-17 Healthwell Acquisition Corp. I DE 001-40697 86-1911840 1001 Green Bay Rd #227 Winnetka IL 60093 (847) 230-9162 false false false false Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant HWELU NASDAQ Class A common stock, par value $0.0001 per share HWEL NASDAQ Redeemable warrants, each warrant exercisable for one share of Class A common stock for $11.50 per share HWELW NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 4 24 1 false 3 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d464704d8k.htm d464704dex101.htm hwelu-20230317.xsd hwelu-20230317_def.xml hwelu-20230317_lab.xml hwelu-20230317_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d464704d8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 30 }, "contextCount": 4, "dts": { "definitionLink": { "local": [ "hwelu-20230317_def.xml" ] }, "inline": { "local": [ "d464704d8k.htm" ] }, "labelLink": { "local": [ "hwelu-20230317_lab.xml" ] }, "presentationLink": { "local": [ "hwelu-20230317_pre.xml" ] }, "schema": { "local": [ "hwelu-20230317.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 32, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 3, "memberStandard": 0, "nsprefix": "hwelu", "nsuri": "http://www.healthwellspac.com/20230317", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d464704d8k.htm", "contextRef": "duration_2023-03-17_to_2023-03-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d464704d8k.htm", "contextRef": "duration_2023-03-17_to_2023-03-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "hwelu_ClassACommonStockParValue0.0001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class A Common Stock Par Value 0.0001 Per Share [Member]", "terseLabel": "Class A Common Stock Par Value 0.0001 Per Share [Member]" } } }, "localname": "ClassACommonStockParValue0.0001PerShareMember", "nsuri": "http://www.healthwellspac.com/20230317", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "hwelu_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://www.healthwellspac.com/20230317", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "hwelu_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://www.healthwellspac.com/20230317", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "hwelu_RedeemableWarrantsEachWarrantExercisableForOneShareOfClassACommonStockFor11.50PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redeemable Warrants Each Warrant Exercisable For One Share Of Class A Common Stock For 11.50 Per Share [Member]", "terseLabel": "Redeemable Warrants Each Warrant Exercisable For One Share Of Class A Common Stock For 11.50 Per Share [Member]" } } }, "localname": "RedeemableWarrantsEachWarrantExercisableForOneShareOfClassACommonStockFor11.50PerShareMember", "nsuri": "http://www.healthwellspac.com/20230317", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "hwelu_UnitsEachConsistingOfOneShareOfClassACommonStockAndOneHalfOfOneRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Units Each Consisting Of One Share Of Class A Common Stock And One Half Of One Redeemable Warrant [Member]", "terseLabel": "Units Each Consisting Of One Share Of Class A Common Stock And One Half Of One Redeemable Warrant [Member]" } } }, "localname": "UnitsEachConsistingOfOneShareOfClassACommonStockAndOneHalfOfOneRedeemableWarrantMember", "nsuri": "http://www.healthwellspac.com/20230317", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.healthwellspac.com//20230317/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001193125-23-078017-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-078017-xbrl.zip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